A Pilot Study to Investigate Platelet Reactivity in Patients With Elevated Lipoprotein(a) and Its… (NCT07720934) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
A Pilot Study to Investigate Platelet Reactivity in Patients With Elevated Lipoprotein(a) and Its Response to Antiplatelet Therapy
Switzerland60 participantsStarted 2026-11-01
Plain-language summary
The Lp(a)-PLAT Study is designed to close a critical evidence gap in cardiovascular prevention for the roughly 20% of the population who carry genetically determined elevations in lipoprotein(a) - a recognised pro-thrombotic and pro-atherosclerotic risk factor. Its objective is to delineate the pro-thrombotic platelet phenotype driven by high Lp(a) levels and to evaluate, through pharmacodynamic comparison, how two standard-of-care antiplatelet strategies - clopidogrel, a P2Y12 ADP-receptor inhibitor, and aspirin, a COX-1 inhibitor - differ in their capacity to attenuate this platelet hyperreactivity.
This study will provide the first head-to-head mechanistic comparison of clopidogrel versus aspirin on platelet reactivity in patients with elevated plasma levels of Lp(a).
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥ 18 years at the time of informed consent.
* Ability to provide written informed consent in accordance with Swiss Human Research Act (HRA) and ICH-GCP.
* Documented plasma lipoprotein(a) \[Lp(a)\] concentration:
High Lp(a) cohort: ≥ 125 nmol/L (approximately ≥ 75th percentile) Low Lp(a) comparator cohort (if applicable): \< 25-30 nmol/L
* Clinically stable at the time of inclusion, with no acute cardiovascular event within the previous 3 months.
* Willingness and ability to comply with all study procedures, including blood sampling and study medication intake.
* For women of childbearing potential: willingness to use adequate contraception during the study period (if applicable according to local ethics requirements).
Exclusion Criteria:
* Cardiovascular and bleeding-related conditions Active bleeding or known bleeding disorder. History of hemorrhagic stroke or intracranial hemorrhage. High risk of bleeding as judged by the investigator. Platelet count \< 100 × 10⁹/L at screening. Known platelet function disorder.
* Contraindications to study medications Known hypersensitivity or contraindication to aspirin (acetylsalicylic acid) or clopidogrel.
History of aspirin-induced asthma, severe NSAID intolerance, or anaphylactic reaction to salicylates.
Active peptic ulcer disease or clinically significant gastrointestinal bleeding within the past 6 months.
\- Concomitant medications and interference with platelet function Current use of dual antipl…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in collagen-induced platelet aggregation after aspirin versus clopidogrel treatment
Timeframe: Baseline and Day 14 of each treatment period (up to 42 days)
2
Change in soluble platelet activation biomarkers after aspirin versus clopidogrel treatment
Timeframe: Baseline and Day 14 of each treatment period (up to 42 days)